NRX PHARMACEUTICALS INC
NRX Pharmaceuticals Inc (NRXP) is a small-cap pharmaceutical company with a market capitalisation of roughly $76.3 million. As with many firms in this sector, NRX may focus on developing or licensing drug candidates rather than generating large commercial revenues today. Investors should know that small-cap biopharma stocks are often driven by clinical or regulatory milestones, partnerships and fundraising activity, which can create sharp share price moves in either direction. Key considerations include the company’s cash runway, the stage of any programmes, intellectual property and potential partners. Because such companies typically carry higher operational and clinical risk, performance can be volatile and future returns are uncertain. This summary is for general educational purposes only and not personal investment advice; suitability depends on an investor’s time horizon, risk tolerance and financial situation.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying NRX Pharmaceuticals' stock, with a target price of $32.5 indicating strong potential growth.
Financial Health
NRX Pharmaceuticals is generating positive cash flow, indicating they have money coming in from operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NRXP
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalysts and Milestones
Clinical readouts, regulatory steps or partnership deals can move the stock materially, though outcomes are uncertain and may increase volatility.
Funding and Runway
Small biotechs often rely on capital markets or partners to fund development; check cash runway and potential dilution risks before investing.
Industry Context
Trends in regulation, competitor progress and licensing opportunities affect prospects, but therapeutic development timelines and outcomes can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
